Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$4.04 USD
+0.24 (6.32%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $4.05 +0.01 (0.25%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 421 - 425 ( 425 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:13 EPS: New Formulation Ready for the Clinic in H1:14, Two Wnt7a Leads Picked for IND-Enabling Studies, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage With an OUTPERFORM Rating and $14 Price Target; Fated to Create Better Stem Cells
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D